Table 1 Comparison of the demographic characteristics, clinical and laboratory data between the IVIG-response and IVIG-resistance patients with KD in total age before initial IVIG treatment

Age (months)

28.50 [14.00–57.00]

24.00 [13.00–42.00]

Male (%)

28(51.9)

199(58.7)

 Rash, n (%)

46(85.2)

263(77.6)

 Bilateral bulbar conjunctive injection, n (%)

48(88.9)

312(92.0)

 Edema & erythema of the extremities, n (%)

33(61.1)

208(61.4)

 Erythema of oral and pharyngeal mucosa, n (%)

53(98.1)

317(93.5)

 Cervical lymphadenopathy, n (%)

29(53.7)

152(44.8)

 Incomplete KD, n (%)

15(27.8)

117(34.5)

 Pericardial effusion (%)

6(11.1)

8(2.4)

 Valve regurgitation (%)

9(16.7)

37(1.9)

 Cardiac enlargement (%)

7(13.0)

30(8.8)

 Ventricular systolic dysfunction (%)

1(1.9)

1(0.3)

 Coronary artery lesions (CALs), n (%)

10(18.5)

35(10.3)

Blood test from fever onset, days

5.00 [4.00–5.00]

5.00 [4.00–5.00]

Fever duration before IVIG administration, days

5.00 [5.00–6.00]

5.00 [5.00–6.00]

 WBC count (10⁹/L)

14.15 [10.83–16.50]

13.40 [10.60–16.70]

 Neutrophils (%)

71.30 [61.15–83.93]

66.20 [56.00–76.20]

 Hemoglobin (g/L)

106.50 [97.75–115.00]

108.00 [101.00–115.00]

 PLT count (10⁹/L)

294.50 [239.25–343.75]

330.00 [276.00–404.00]

 CRP (mg/L)

85.00 [61.75–137.50]

69.00 [41.00–103.00]

 ESR (mm/h)

66.00 [45.50–94.00]

64.00 [47.00–81.00]

 AST (IU/L)

30.50 [23.00–57.50]

30.00 [24.00–47.00]

 ALT (IU/L)

44.00 [25.75–96.50]

36.00 [20.00–74.00]

 ALB (g/L)

36.05 [32.00–38.90]

37.60 [35.20–41.10]

 Total bilirubin (mg/L)

6.80 [4.75–12.90]

6.10 [3.70–8.70]

 Urea nitrogen (mmol/L)

2.90 [2.40–3.50]

2.70 [2.10–3.20]

 Creatinine (umol/L)

29.00 [24.00–36.00]

27.00 [22.00–31.00]

 Sodium (mmol/L)

135.00 [132.75–137.00]

137.00 [135.00–139.00]

 Potassium (mmol/L)

4.04 [3.50–4.41]

4.12 [3.77–4.56]

Troponin (ug/L)

0.12 [0.12–0.13]

0.12 [0.12–0.12]